SCHEMBL4834852

SCHEMBL4834852

CCOc1ccc2cc(OBOc3ccc4cc(OCC)ccc4c3)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.52
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CYP1A2 P05177 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
CYP19A1 P11511 1/20 0.46
TSHR P16473 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629327 0.87 NQO1 (0.68) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL3825385 0.87 NQO1 (0.68) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL23583 0.83 TP53 (0.57) NQO1CYP1A2TSHRTDP1KMT2A
SCHEMBL23298 0.82 NQO1 (0.70) NQO1CA12CA1CA7CA9
SCHEMBL23458226 0.82 NQO1 (0.62) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL29779700 0.82 NQO1 (0.62) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL3821099 0.82 NQO1 (0.62) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL18417197 0.78 NQO1 (0.56) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL2662879 0.78 CYP11B1 (0.65) NQO1AKR1C3AKR1C2CA12CA1
SCHEMBL111274 0.78 AGXT (0.63) NQO1CA12CA1CYP1A2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449484-B2 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-11 US disclosed
EP-1343779-B1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-27 EP disclosed
US-20060166988-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2006-07-27 US disclosed
US-20040053943-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed
EP-1343779-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1343779-A2 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2003-09-17 EP disclosed
WO-2002039954-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053943-A1 Novel compounds TIE1, TEK, VEGFA NQO1 1746/4885AKR1C3 1036/4885AKR1C2 886/4885
US-20060166988-A1 Novel compounds TIE1, TEK, VEGFA NQO1 1746/4885AKR1C3 1036/4885AKR1C2 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.